Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire.

IF 1.2 Q3 DERMATOLOGY
Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-09 DOI:10.1155/2015/953479
Erica H Lee, Rajiv I Nijhawan, Kishwer S Nehal, Stephen W Dusza, Amanda Levine, Amanda Hill, Christopher A Barker
{"title":"Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire.","authors":"Erica H Lee,&nbsp;Rajiv I Nijhawan,&nbsp;Kishwer S Nehal,&nbsp;Stephen W Dusza,&nbsp;Amanda Levine,&nbsp;Amanda Hill,&nbsp;Christopher A Barker","doi":"10.1155/2015/953479","DOIUrl":null,"url":null,"abstract":"<p><p>Background. Comorbidities are conditions that occur simultaneously but independently of another disorder. Among skin cancer patients, comorbidities are common and may influence management. Objective. We compared comorbidity assessment by traditional medical interview (MI) and by standardized patient-reported questionnaire based on the Adult Comorbidity Evaluation-27 (ACE-27). Methods. Between September 2011 and October 2013, skin cancer patients underwent prospective comorbidity assessment by a Mohs surgeon (MI) and a radiation oncologist (using a standardized patient-reported questionnaire based on the ACE-27, the PRACE-27). Comorbidities were identified and graded according to the ACE-27 and compared for agreement. Results. Forty-four patients were evaluated. MI and PRACE-27 identified comorbidities in 79.5% and 88.6% (p = 0.12) of patients, respectively. Among 27 comorbid ailments, the MI identified 9.9% as being present, while the PRACE-27 identified 12.5%. When there were discordant observations, PRACE-27 was more likely than MI to identify the comorbidity (OR = 5.4, 95% CI = 2.4-14.4, p < 0.001). Overall comorbidity scores were moderate or severe in 43.2% (MI) versus 59.1% (PRACE-27) (p = 0.016). Limitations. Small sample size from a single institution. Conclusion. Comorbidities are common in skin cancer patients, and a standardized questionnaire may better identify and grade them. More accurate comorbidity assessments may help guide skin cancer management. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"953479"},"PeriodicalIF":1.2000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/953479","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Skin Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2015/953479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/6/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 10

Abstract

Background. Comorbidities are conditions that occur simultaneously but independently of another disorder. Among skin cancer patients, comorbidities are common and may influence management. Objective. We compared comorbidity assessment by traditional medical interview (MI) and by standardized patient-reported questionnaire based on the Adult Comorbidity Evaluation-27 (ACE-27). Methods. Between September 2011 and October 2013, skin cancer patients underwent prospective comorbidity assessment by a Mohs surgeon (MI) and a radiation oncologist (using a standardized patient-reported questionnaire based on the ACE-27, the PRACE-27). Comorbidities were identified and graded according to the ACE-27 and compared for agreement. Results. Forty-four patients were evaluated. MI and PRACE-27 identified comorbidities in 79.5% and 88.6% (p = 0.12) of patients, respectively. Among 27 comorbid ailments, the MI identified 9.9% as being present, while the PRACE-27 identified 12.5%. When there were discordant observations, PRACE-27 was more likely than MI to identify the comorbidity (OR = 5.4, 95% CI = 2.4-14.4, p < 0.001). Overall comorbidity scores were moderate or severe in 43.2% (MI) versus 59.1% (PRACE-27) (p = 0.016). Limitations. Small sample size from a single institution. Conclusion. Comorbidities are common in skin cancer patients, and a standardized questionnaire may better identify and grade them. More accurate comorbidity assessments may help guide skin cancer management.

皮肤癌患者的合并症评估:一项比较医学访谈与患者报告问卷的初步研究
背景。合并症是指同时发生但独立于另一种疾病的情况。在皮肤癌患者中,合并症是常见的,并可能影响管理。目标。我们比较了传统医学访谈(MI)和基于成人共病评估-27 (ACE-27)的标准化患者报告问卷的共病评估。方法。在2011年9月至2013年10月期间,皮肤癌患者接受了Mohs外科医生(MI)和放射肿瘤学家(使用基于ACE-27和pace -27的标准化患者报告问卷)的前瞻性合并症评估。根据ACE-27对合并症进行鉴定和分级,并比较其一致性。结果。对44例患者进行了评估。MI和pace -27分别鉴定出79.5%和88.6% (p = 0.12)的患者存在合并症。在27种共病中,MI鉴定为9.9%,而pace -27鉴定为12.5%。当观察结果不一致时,pace -27比MI更有可能识别共病(OR = 5.4, 95% CI = 2.4-14.4, p < 0.001)。43.2% (MI)和59.1% (pce -27)的总体合并症评分为中度或重度(p = 0.016)。的局限性。来自单一机构的小样本。结论。合并症在皮肤癌患者中很常见,标准化的问卷调查可以更好地识别和分级。更准确的合并症评估可能有助于指导皮肤癌的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Skin Cancer
Journal of Skin Cancer DERMATOLOGY-
CiteScore
2.30
自引率
18.20%
发文量
12
审稿时长
21 weeks
期刊介绍: Journal of Skin Cancer is a peer-reviewed, Open Access journal that publishes clinical and translational research on the detection, diagnosis, prevention, and treatment of skin malignancies. The journal encourages the submission of original research articles, review articles, and clinical studies related to pathology, prognostic indicators and biomarkers, novel therapies, as well as drug sensitivity and resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信